Device Trial Radar · NCT06214221
Using Signos mHealth Platform in Adults for Weight Management
Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
380
Actual
Start
Jan 2, 2024
Primary completion
Dec 31, 2024
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Signos IncNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Lindus Health, Inc.
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.
Conditions
- Overweight and Obesity
- Metabolic Syndrome
- Weight Loss
Interventions
Signos SystemDevice
The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.
Standard Lifestyle EducationOther
In the "Standard Lifestyle Education" arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder RateTime frame: 6 Months
- Average Total Body Weight Loss (TBWL%)Time frame: 6 Months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Helios Clinical Research (Phoenix)
Phoenix, Arizona
Diablo Clinical Research
Walnut Creek, California
Segal Trials
North Miami, Florida
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.